ADHD Medication Shortage 2026: Adderall and Vyvanse Costs and How to Pay Less

Adderall is the brand name for mixed amphetamine salts (MAS), a Schedule II controlled substance that contains amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate in a 3:1 dextro-to-levo ratio. It is FDA-approved for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. Generic mixed amphetamine salts are produced by multiple manufacturers, including Teva, Sandoz, Mallinckrodt, Amneal, and Lannett. Vyvanse is the brand name for lisdexamfetamine dimesylate, a prodrug that converts to d-amphetamine in the body; the FDA approved 15 generic manufacturers to produce generic lisdexamfetamine in August 2023.

The ongoing shortage began in October 2022 when Teva, the largest manufacturer of brand Adderall, reported supply disruptions. The FDA posted an official shortage notice that same month. As of June 2026, both the FDA and the American Society of Health-System Pharmacists (ASHP) still list amphetamine mixed salts IR and XR as in active shortage. The DEA raised the aggregate production quota (APQ) for d-amphetamine from 21.2 million grams to 26.5 million grams (a 25% increase) in October 2025, and then increased it further by approximately 14% above the originally proposed 2026 level following more than 5,000 public comments. These quota increases have improved availability for some dose strengths, but 20 mg, 25 mg, and 30 mg formulations remain intermittently unavailable. Patients managing costs during the shortage can also check Medicaid income limits to see whether they qualify for near-zero copays on any available formulation.

Adderall and Vyvanse are classified as oral, self-administered drugs dispensed at retail pharmacies, so both are billed exclusively through Medicare Part D, not Part B. No HCPCS J-code applies to either medication. Patients pay under their Part D plan's formulary tier system, subject to the 2026 annual out-of-pocket cap of $2,100 across all Part D drugs combined. Most Part D plans cover generic amphetamine salts on Tier 2 (preferred generic) or Tier 3, and generic lisdexamfetamine on Tier 2 or Tier 3. Prior authorization is nearly universal for stimulant medications, requiring documentation of an ADHD or narcolepsy diagnosis. To review Medicare coverage options, see the Medicare eligibility guide.

What ADHD Meds Shortage Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same adhd meds shortage can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

When a patient is admitted to a hospital for any reason and continues receiving a Schedule II stimulant like Adderall or Vyvanse, the hospital bills the medication at its facility acquisition and handling rate rather than retail pharmacy cost. Hospitals that stock Schedule II controlled substances must maintain locked, tamper-evident storage (per DEA 21 CFR Part 1301), chain-of-custody logging, pharmacist verification for each dose dispensed, and mandatory controlled-substance reconciliation reports. These regulatory requirements add real administrative overhead on top of the raw drug acquisition cost, driving inpatient line-item charges for Schedule II drugs above retail.

For most ADHD patients, the more pressing concern during a hospitalization is not the inpatient charge but whether the hospital will continue the outpatient Schedule II prescription at all. Many hospital formularies require a psychiatry or neurology consult before continuing a stimulant for a patient admitted for a non-psychiatric condition. If the hospital does not carry the specific dose strength (shortage has made this more common since 2022), the patient may need to arrange a temporary medication hold or dose adjustment with their outpatient prescriber. Patients who receive an unexpected or unexplained charge for controlled-substance administration during an inpatient stay can use the CoveredUSA Medical Bill Analyzer to identify billing errors such as wrong-drug or double-billing.

Patient Assistance Programs

Most generic amphetamine salt manufacturers do not run traditional patient assistance programs because the generic is already low-cost at $11 to $48 per month with a GoodRx coupon. For uninsured or underinsured patients who need brand-name Adderall XR or Vyvanse, Takeda runs the Help at Hand program. For generic versions, GoodRx, RxSaver, and Cost Plus Drugs are typically faster and more practical than formal PAP applications. Compare the retail cash price without insurance ($47 to $300 per month for generic IR/XR depending on dose and pharmacy) against PAP eligibility to determine the best path for your household.

Medicare Part D

Adderall (mixed amphetamine salts) and Vyvanse (lisdexamfetamine) are Part D drugs covered through Medicare prescription drug plans. Because both are oral, self-administered medications, Medicare Part B does not cover them. Coverage depends on your specific plan's formulary: most Part D plans include generic mixed amphetamine salts IR and XR on Tier 2 (preferred generic) or Tier 3, and generic lisdexamfetamine on Tier 2 or Tier 3. Brand Adderall XR and brand Vyvanse, where still prescribed, are typically on Tier 4 (non-preferred brand) or Tier 5. Prior authorization is nearly universal for stimulant medications under Medicare Part D. Your prescriber must document a qualifying ADHD or narcolepsy diagnosis, and some plans impose quantity limits such as one tablet per day.

Medicare Part D out-of-pocket costs for ADHD stimulants in 2026 are capped by the Inflation Reduction Act annual limit of $2,100. Once you have spent $2,100 in true out-of-pocket costs across all your covered Part D drugs, your plan pays 100% for the remainder of the calendar year. There is no special monthly cap for stimulants equivalent to the $35/month insulin cap established by the Inflation Reduction Act of 2022. Neither Adderall nor Vyvanse has been selected for Medicare drug price negotiation under the IRA, so no Maximum Fair Price applies to these medications in 2026. The IRA Round-2 selection list (effective 2027) does not currently include amphetamine-class drugs. For patients who have low income and qualify for Medicaid or Medicare Extra Help (Low Income Subsidy), copays may be reduced to $0 to $10 per prescription regardless of tier placement. Check eligibility at medicare.gov.

Common ADHD Meds Shortage Billing Errors

Adderall and Vyvanse are oral Schedule II controlled substances not billed with HCPCS J-codes. Billing errors for stimulant medications occur most often in these patterns:

• Brand billed when generic was dispensed: the pharmacy fills with generic amphetamine salts but submits the claim as brand Adderall XR, charging the patient a brand-tier cost instead of the generic-tier copay.
• Shortage substitution billing error: when a pharmacy substitutes one dose strength for another due to shortage without updating the insurance claim, the claim may be billed under the wrong NDC code at a different tier.
• Wrong days-supply submitted (30-day vs. 90-day fills): if the pharmacy submits a 30-day supply claim code for a 90-day fill, the patient's out-of-pocket calculation is incorrect, often resulting in overpayment.
• Prior authorization denial applied to patient without appeal option: if the PA was not obtained but the prescription was dispensed, the full cost may be charged to the patient without the pharmacy triggering an automatic appeal pathway.
• Formulary tier reclassification mid-year: if your plan changes the tier placement for a stimulant mid-year (allowable in certain circumstances), the patient may suddenly face a higher copay without notice. Review your plan's Evidence of Coverage for rules on mid-year tier changes.

Frequently Asked Questions